

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI330761

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
The Scripps Research Institute	04/01/2022
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	University of Florida Board of Trustees
<b>Street Address:</b>	111 Tigert Hall
<b>Internal Address:</b>	P.O. Boxs 113157
<b>City:</b>	Gainesville
<b>State/Country:</b>	FLORIDA
<b>Postal Code:</b>	32611
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17078903
<b>Application Number:</b>	15503971
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	6102515786
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(610)251-5786
<b>Email:</b>	lisa.sapovits@saul.com,patents@saul.com
<b>Correspondent Name:</b>	Lisa R Sapovits
<b>Address Line 1:</b>	Saul Ewing LLP
<b>Address Line 2:</b>	1200 Liberty Ridge Drive, Suite 200
<b>Address Line 4:</b>	Wayne, PENNSYLVANIA 19087-5569
<b>ATTORNEY DOCKET NUMBER:</b>	046483-7023US1/7023US2
<b>NAME OF SUBMITTER:</b>	Lisa Sapovits
<b>SIGNATURE:</b>	Lisa Sapovits
<b>DATE SIGNED:</b>	06/28/2024
<b>Total Attachments: 11</b>	
source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP list_Redacted#page11.tiff	
source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP	

list\_Redacted#page10.tiff

source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP list\_Redacted#page8.tiff

source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP list\_Redacted#page5.tiff

source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP list\_Redacted#page9.tiff

source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP list\_Redacted#page4.tiff

source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP list\_Redacted#page2.tiff

source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP list\_Redacted#page7.tiff

source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP list\_Redacted#page1.tiff

source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP list\_Redacted#page3.tiff

source=Pages from S-T00198 Assignment from TSRI to BOT to UFRF with Schedule 1 IP list\_Redacted#page6.tiff

**PATENT**

**REEL: 067978 FRAME: 0682**

**ASSIGNMENT - WORLDWIDE**

THIS ASSIGNMENT, made by, UNIVERSITY OF FLORIDA BOARD OF TRUSTEES, a Florida not for profit corporation, having its office at 111 Tigert Hall, P.O. Box 113157, Gainesville, FL 32611, hereinafter referred to as Assignor;

WITNESSETH: That,

WHEREAS, Assignor has previously acquired all right, title, and interest in and to the intellectual property identified on the attached Schedule 1, in and to all corresponding patents, patent applications, utility models, design registrations, other rights of exclusion, and/or inventors' certificates in every country or region worldwide, and in and to all inventions represented thereby (all hereinafter referred to collectively as the "Assigned Intellectual Property" on the attached Schedule 1); and,

WHEREAS, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, a Florida not for profit corporation, having its office at 223 Grinter Hall, Gainesville, Florida 32611, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in and to the Assigned Intellectual Property; and

WHEREAS, the parties have agreed to the Assignment hereinafter set forth;

NOW, THEREFORE, To All Whom It May Concern, be it known that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the above Assignor has sold and by these presents does hereby sell, assign, transfer, and convey unto the said Assignee, its successors and assigns, its entire right, title, and interest in and to the Assigned Intellectual Property, together with every priority right that is or may be predicated upon or arise from any of the Intellectual Property; and the right to pursue, collect, and retain in Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Assigned Intellectual Property assigned by this Assignment; all to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made.

From time to time after the date hereof, at the request of either party hereto, and at the expense of the party so requesting, each of the parties hereto shall execute and deliver to such requesting party such documents and take such other action as such requesting party may reasonably request in order to consummate more effectively the transactions contemplated hereby.

The Assignor further covenants and agrees that, at the time of the execution and delivery of these presents, it possesses full title to the Assigned Intellectual Property, and that it has the unencumbered right and authority to make this Assignment.

*Remainder of Page Intentionally Left Blank*

**IN WITNESS WHEREOF**, the Parties have caused this Assignment and Assumption Agreement of Transferred IP Assets to be executed as of the date first above written.

**ASSIGNOR:**

THE SCRIPPS RESEARCH INSTITUTE

By: DocuSigned by: Matt Tremblay

Name: Matt Tremblay

Title: COO

**ASSIGNEE:**

UNIVERSITY OF FLORIDA BOARD OF TRUSTEES

By: \_\_\_\_\_

Name: David Nelson

Title: President, UF Health

## ASSIGNMENT AND ASSUMPTION AGREEMENT OF TRANSFERRED IP ASSETS

This ASSIGNMENT AND ASSUMPTION AGREEMENT OF TRANSFERRED IP ASSETS (this “**Agreement**”) is made and entered into as of April 1, 2022 (the “**Effective Date**”), by and between The Scripps Research Institute, a California nonprofit public benefit corporation and registered to do business in Florida (“**Assignor**”) and University of Florida Board of Trustees, a Florida not for profit corporation (“**Assignee**”). Assignor and Assignee are referred to herein, individually, as a “**Party**” or, collectively, as the “**Parties**.”

### WITNESSETH:

WHEREAS, Assignor and Assignee are parties to that certain Asset Transfer Agreement dated November 15, 2021, as amended by that certain Amendment No. 1 to the Asset Transfer Agreement, dated December 22, 2021 (together, the “**Asset Transfer Agreement**”), pursuant to which, among other things, Assignor has agreed to assign to Assignee, and Assignee has agreed to accept from Assignor, as of the Closing, all of Assignor’s right, title and interest in and to all Transferred IP Assets,

WHEREAS, to provide a document for recording, as applicable, with the United States Patent and Trademark Office, the United States Copyright Office, and the corresponding entities or agencies in any applicable jurisdictions, Assignor and Assignee are executing this Agreement.

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Parties agree as follows:

1. **Definitions.** All capitalized terms used, but not defined herein, shall have the meanings ascribed to such terms in the Asset Transfer Agreement.

2. **Recitals.** The recitals set forth above are, by this reference, incorporated into and deemed part of this Agreement.

3. **Assignment.** For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby irrevocably sells, transfers, assigns, and delivers to Assignee all of Assignor’s respective right, title and interest in and to all Transferred IP Assets, including without limitation (i) the Intellectual Property within the Transferred IP Assets set forth in Schedule 1 hereof, (ii) all common law rights and goodwill associated therewith, and the entire right, title and interest in and to any and all royalties, fees, income, payments, and other proceeds now or hereafter due or payable to TSRI with respect to such Intellectual Property, as well as Actions and causes of action in favor of TSRI with respect to such Intellectual Property, whether accruing before, on, or after the date hereof/accruing on or after the date hereof, including all rights to and Actions for damages, restitution, and injunctive and other legal or equitable relief for past, present, or future infringement, misappropriation, or other violation thereof, to have and to hold such Intellectual Property forever, (iii) the right to secure registration of such Intellectual Property and of this Agreement, (iv) the right to initiate other proceedings before all government and administrative bodies with respect to such Intellectual Property, and the right to claim priority, file foreign counterparts and make applications for reissue and reexamination with respect to any of such Intellectual Property.

4. **Acceptance.** Assignee hereby accepts the foregoing assignment of all Transferred IP Assets, pursuant to this Agreement, and assumes all right, title and interest of Assignor with respect to the Transferred IP Assets.

5. **Recordation and other actions.** Assignor hereby authorizes the Commissioner for Patents in the United States Patent and Trademark Office, the Register of Copyrights in the United States Copyright Office, and the officials of corresponding entities or agencies in any applicable jurisdictions, to record and

register this Agreement and to record the Assignee as the owner of the Transferred IP Assets and all Intellectual Property therein upon request by Assignee. Following the date hereof, upon Assignee's reasonable request, Assignor shall at Assignee's expense take such steps and actions, and provide such cooperation and assistance to Assignee and its successors, assigns, and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documents, as may be reasonably necessary to effect or perfect the assignment of the Transferred IP Assets to Assignee, or any other assignee or successor thereto.

6. Terms of the Asset Transfer Agreement. The Parties acknowledge and agree that this Agreement is entered into pursuant to the Asset Transfer Agreement, to which reference is made for a further statement of the rights and obligations of the Assignee and Assignor with respect to the Transferred IP Assets. Notwithstanding anything to the contrary contained in this Agreement, nothing contained herein is intended to or shall be deemed to limit, restrict, modify, alter, amend or otherwise change in any manner the rights and obligations of Assignor or Assignee under the Asset Transfer Agreement. Nothing herein shall be deemed to enlarge, modify or alter in any way the representations and warranties or the rights and remedies of the Parties under the Asset Transfer Agreement. The representations, warranties, covenants, agreements, and indemnities contained in the Asset Transfer Agreement and the Conveyance will not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of a conflict or inconsistency between the terms of the Asset Transfer Agreement and the terms of this Agreement, the terms of the Asset Transfer Agreement will govern.

7. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement.

8. Further Assurances. Assignor and Assignee each agree to do such further acts and things and to execute and deliver such additional agreements and instruments as may reasonably be required to consummate, evidence or confirm the assignments and agreements contained herein. Without limiting the foregoing, Assignor shall upon Assignee's request transfer to Assignee or its designee the files and records of Assignor concerning the prosecution of all Intellectual Property within the Transferred IP Assets.

9. Section Headings. The descriptive headings herein are inserted for convenience only and are not intended to be part of or to affect the meaning or interpretation of this Agreement.

10. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida (without giving effect to conflict of law principles) as to all matters, including but not limited to matters of validity, construction, effect, performance and remedies.

11. Successors. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their successors and assigns.

12. Severability. In the event that any provision of this Agreement shall be unenforceable or inoperative as a matter of law, the remaining provisions shall remain in full force and effect.

13. Authority. Each Party represents and warrants to the other that it is fully authorized to execute and deliver this Agreement, and that the individual signing this Agreement on behalf of such Party is fully authorized to do so.

*[Signature Page Follows]*

**IN WITNESS WHEREOF**, the Parties have caused this Assignment and Assumption Agreement of Transferred IP Assets to be executed as of the date first above written.

**ASSIGNOR:**

THE SCRIPPS RESEARCH INSTITUTE


By: \_\_\_\_\_

Name: Matt Tremblay

Title: COO

**ASSIGNEE:**

UNIVERSITY OF FLORIDA BOARD OF TRUSTEES

By:  \_\_\_\_\_  
C2B896DD6B0242A...

Name: David Nelson

Title: President, UF Health



IN WITNESS WHEREOF, the Assignor has caused this assignment to be executed this  
1st day of April, 2022.

**ASSIGNOR:**

UNIVERSITY OF FLORIDA BOARD OF TRUSTEES

By: Nelson, David

Print Name: David Nelson

Title: President, UF Health

IN WITNESS WHEREOF, the Assignee has caused this assignment to be executed this  
1st day of April, 2022.

**ASSIGNEE:**

UNIVERSITY OF FLORIDA RESEARCH  
FOUNDATION, INCORPORATED

By: 

Print Name: Jim O'Connell

Title: Director, UF Innovate | Tech Licensing

81) (U.S. NATIONAL  
PHASE)

[REDACTED]

				THYROID CARCINOMA (PROVISIONAL)
				GLYCOSYL- PHOSPHATIDYLINOSITOL (GPI)-LINKED GDNF FAMILY ALPHA- RECEPTOR 4 (GFR ALPHA 4)-SPECIFIC ANTIBODY AND USES THEREOF (PCT) TREATMENT OF CANCER USING GFR ALPHA-4
FLA 0208P	15/045355	WO 16/025884	SIEGEL, MILONE, KACIR, RADER	
FLA 0258P	2015301460	2015301460	SIEGEL, MILONE, BHOJ, RADER	CHIMERIC ANTIGEN RECEPTOR (AUSTRALIA) TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (AUSTRALIA/DIV 1) TREATMENT OF CANCER USING GFR ALPHA-4
FLA 0477P	2021203514		SIEGEL, MILONE, BHOJ, RADER	CHIMERIC ANTIGEN RECEPTOR (CANADA)
FLA 0259P	2,958,200		SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (DISCL. NO. 14- 81) (DIV 1)
FLA 0461P	17/078,903		SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (EPO)
FLA 0260P	15757371.8		SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (HONG KONG)
FLA 0308P	17113522.1		SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (JAPAN) TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (DISCL. NO. 14- 81) (PCT)
FLA 0261P	2017-508039	6919118	SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (DISCL. NO. 14- 81) (PCT)
FLA 0257P	15/045349	WO 16/025880	SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (DISCL. NO. 14- 81)
FLA 0262P	15/503,971	10,851,149	SIEGEL, MILONE, BHOJ, RADER	TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR (DISCL. NO. 14-

Schedule 1

Intellectual Property

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Patents

TSRI Reference Number	Serial Number	Patent Number	Inventors	Title
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

FLA 0150P 62/037,434

FLA 0275P 62/037,383

SIEGEL, MILONE,  
KACIR, RADER

SIEGEL, MILONE,  
BHOJ, RADER

GLYCOSYL-  
PHOSPHATIDYLINOSITOL  
(GPI)-LINKED GDNF  
FAMILY ALPHA-  
RECEPTOR 4 (GFR ALPHA  
4)-SPECIFIC ANTIBODY  
AND USES THEREOF  
(DISCL. NO. 14-81)  
(PROVISIONAL)

CAR-T CELL THERAPY  
FOR MEDULLARY